NEW YORK and LONDON, April 24, 2017
-Interim Phase 2 PNH data demonstrate positive response with Coversin™
-Phase 3 PNH program expected to commence in 4Q2017
-Data from preclinical aHUS model demonstrates positive results
-New preclinical data demonstrates positive response of Coversin’s combined C5 and LTB4 therapy in skin and eye models
-Phase 2 programs in Mucous Membrane Pemphigoid (eye) and Bullous Pemphigoid (Skin) expected to commence in 1Q2018
-Company to webcast today’s Research and Development Day at 8:00 am Eastern (details in full press release)-
Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced that it will present data from an interim analysis of its ongoing Phase 2 trial of Coversin in paroxysmal nocturnal hemoglobinuria (PNH), as well as preclinical data for additional indications and other opportunities, at today’s Research and Development Day.
